Activity-based kinase profiling of approved tyrosine kinase inhibitors

Genes to Cells

Volumn 18, Issue 2, 2013, Pages 110-122

  Kitagawa, Daisuke ^a   Yokota, Koichi ^a   Gouda, Masaki ^a   Narumi, Yugo ^a   Ohmoto, Hiroshi ^a   Nishiwaki, Eiji ^a   Akita, Kensaku ^a   Kirii, Yasuyuki ^a  

^a 1 5 5 Minatojima Minamimachi   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LIPID; NILOTINIB; PAZOPANIB; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STAUROSPORINE; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CALCULATION; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DRUG INHIBITION; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MUTATION; PHYLOGENY; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOME; REPRODUCIBILITY OF RESULTS;

EID: 84873056956     PISSN: 13569597     EISSN: 13652443     Source Type: Journal    
DOI: 10.1111/gtc.12022     Document Type: Article

References (57)

1. Accili, D., Drago, J., Lee, E.J., Johnson, M.D., Cool, M.H., Salvatore, P., Asico, L.D., Jose, P.A., Taylor, S.I. & Westphal, H. (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12, 106-109.
2. Ahmed, A.A., Lu, Z., Jennings, N.B., et al. (2010) SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18, 109-121.
3. Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C.G., Schwartz, B. & Piccart, M. (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861.
4. Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. (2003) The specificities of protein kinase inhibitors: an update. Biochem J. 371, 199-204.
5. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C.J., McLauchlan, H., Klevernic, I., Arthur, J.S., Alessi, D.R. & Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J. 408, 297-315.
6. Bankston, D., Dumas, J., Natero, R., Riedl, B., Monahan, M.-K. & Sibley, R. (2002) A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer. Org. Proc. Res. Dev. 6, 777-781.
7. Bantscheff, M., Eberhard, D., Abraham, Y., et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044.
8. Bukowski, R.M., Yasothan, U. & Kirkpatrick, P. (2010) Pazopanib. Nat. Rev. Drug. Discov. 9, 17-18.
9. Burris, H.A. III, Taylor, C.W., Jones, S.F., Koch, K.M., Versola, M.J., Arya, N., Fleming, R.A., Smith, D.A., Pandite, L., Spector, N. & Wilding, G. (2009) A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin. Cancer Res. 15, 6702-6708.
10. Chintalgattu, V., Ai, D., Langley, R.R., et al. (2010) Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120, 472-484.
11. Chu, T.F., Rupnick, M.A., Kerkela, R., et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019.
12. Cohen, M.H., Williams, G., Johnson, J.R., Duan, J., Gobburu, J., Rahman, A., Benson, K., Leighton, J., Kim, S.K., Wood, R., Rothmann, M., Chen, G., U, K.M., Staten, A.M. & Pazdur, R. (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935-942.
13. Cohen, M.H., Williams, G.A., Sridhara, R., Chen, G. & Pazdur, R. (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8, 303-306.
14. Cohen, P. (2001) The role of protein phosphorylation in human health and disease The Sir Hans Krebs Medal Lecture. Eur. J. Biochem. 268, 5001-5010.
15. Cohen, P. (2002) Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug. Discov. 1, 309-315.
16. Dagher, R., Cohen, M., Williams, G., Rothmann, M., Gobburu, J., Robbie, G., Rahman, A., Chen, G., Staten, A., Griebel, D. & Pazdur, R. (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8, 3034-3038.
17. Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105.
18. Demetri, G.D., Lo Russo, P., MacPherson, I.R., Wang, D., Morgan, J.A., Brunton, V.G., Paliwal, P., Agrawal, S., Voi, M. & Evans, T.R. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin. Cancer Res. 15, 6232-6240.
19. Ding, P., Huang, J., Battiprolu, P.K., Hill, J.A., Kamm, K.E. & Stull, J.T. (2010) Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo. J. Biol. Chem. 285, 40819-40829.
20. Fabian, M.A., Biggs, W.H. III, Treiber, D.K., et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
21. Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Muller, S., Bullock, A.N., Schwaller, J., Sundstrom, M. & Knapp, S. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl Acad. Sci. USA 104, 20523-20528.
22. Force, T. & Kolaja, K.L. (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111-126.
23. Gajiwala, K.S., Wu, J.C., Christensen, J., et al. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl Acad. Sci. USA 106, 1542-1547.
24. Goodman, V.L., Rock, E.P., Dagher, R., et al. (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367-1373.
25. Hasinoff, B.B. (2010) The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244, 190-195.
26. Herbst, R.S., Maddox, A.M., Rothenberg, M.L., Small, E.J., Rubin, E.H., Baselga, J., Rojo, F., Hong, W.K., Swaisland, H., Averbuch, S.D., Ochs, J. & LoRusso, P.M. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20, 3815-3825.
27. Houk, B.E., Bello, C.L., Kang, D. & Amantea, M. (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15, 2497-2506.
28. Hurtado, B., Munoz, X., Recarte-Pelz, P., Garcia, N., Luque, A., Krupinski, J., Sala, N. & Garcia de Frutos, P. (2011) Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques. Thromb. Haemost. 105, 873-882.
29. Hurwitz, H.I., Dowlati, A., Saini, S., Savage, S., Suttle, A.B., Gibson, D.M., Hodge, J.P., Merkle, E.M. & Pandite, L. (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15, 4220-4227.
30. Imamura, H., Nhat, K.P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y., Nagai, T. & Noji, H. (2009) Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc. Natl Acad. Sci. USA 106, 15651-15656.
31. Kantarjian, H., Giles, F., Wunderle, L., et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551.
32. Karaman, M.W., Herrgard, S., Treiber, D.K., et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132.
33. Khorashad, J.S., Milojkovic, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A.G., De Melo, V., Babb, A., de Lavallade, H., Olavarria, E., Marin, D., Goldman, J.M., Apperley, J.F. & Kaeda, J.S. (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111, 2378-2381.
34. Kinoshita, T., Miyano, N., Nakai, R., Yokota, K., Ishiguro, H. & Tada, T. (2008) Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase. Protein Expr. Purif. 58, 318-324.
35. Kitagawa, D., Gouda, M., Kirii, Y., Sugiyama, N., Ishihama, Y., Fujii, I., Narumi, Y., Akita, K. & Yokota, K. (2012) Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. J. Biochem. 151, 47-55.
36. Knight, Z.A. & Shokat, K.M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621-637.
37. Li, M., Naqvi, N., Yahiro, E., Liu, K., Powell, P.C., Bradley, W.E., Martin, D.I., Graham, R.M., Dell'Italia, L.J. & Husain, A. (2008) c-kit is required for cardiomyocyte terminal differentiation. Circ. Res. 102, 677-685.
38. Lombardo, L.J., Lee, F.Y., Chen, P., et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
39. Manley, P.W., Drueckes, P., Fendrich, G., Furet, P., Liebetanz, J., Martiny-Baron, G., Mestan, J., Trappe, J., Wartmann, M. & Fabbro, D. (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta 1804, 445-453.
40. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934.
41. Minna, J.D. & Dowell, J. (2005) Erlotinib hydrochloride. Nat. Rev. Drug Discov. Suppl, S14-S15.
42. Motzer, R.J. & Bukowski, R.M. (2006) Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24, 5601-5608.
43. Piccaluga, P.P., Paolini, S. & Martinelli, G. (2007) Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110, 1178-1186.
44. Quintas-Cardama, A. & Cortes, J. (2008) Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol. 4, 611-621.
45. Rock, E.P., Goodman, V., Jiang, J.X., Mahjoob, K., Verbois, S.L., Morse, D., Dagher, R., Justice, R. & Pazdur, R. (2007) Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12, 107-113.
46. Ryan, Q., Ibrahim, A., Cohen, M.H., Johnson, J., Ko, C.W., Sridhara, R., Justice, R. & Pazdur, R. (2008) FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13, 1114-1119.
47. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. & Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942.
48. Sun, L., Liang, C., Shirazian, S., et al. (2003) Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]-2, 4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116-1119.
49. Tan, A.R., Yang, X., Hewitt, S.M., et al. (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 22, 3080-3090.
50. Thirunavukkarasu, M., Addya, S., Juhasz, B., Pant, R., Zhan, L., Surrey, S., Maulik, G., Menon, V.P. & Maulik, N. (2008) Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis. J. Cell Mol. Med. 12, 1284-1302.
51. Walter, M., Lucet, I.S., Patel, O., Broughton, S.E., Bamert, R., Williams, N.K., Fantino, E., Wilks, A.F. & Rossjohn, J. (2007) The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J. Mol. Biol. 367, 839-847.
52. Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A. & Griffin, J.D. (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94, 1765-1769.
53. White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M.F., Lynch, K., To, L.B. & Hughes, T. (2007) Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J. Clin. Oncol. 25, 4445-4451.
54. Widmer, N., Decosterd, L.A., Leyvraz, S., Duchosal, M.A., Rosselet, A., Debiec-Rychter, M., Csajka, C., Biollaz, J. & Buclin, T. (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br. J. Cancer 98, 1633-1640.
55. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R. & Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844.
56. Zhang, P., Hu, X., Xu, X., Fassett, J., Zhu, G., Viollet, B., Xu, W., Wiczer, B., Bernlohr, D.A., Bache, R.J. & Chen, Y. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52, 918-924.
57. Zsila, F., Fitos, I., Bencze, G., Keri, G. & Orfi, L. (2009) Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr. Med. Chem. 16, 1964-1977.